SCHEMBL16119992

SCHEMBL16119992

CNCCN(C)Cc1n[nH]c2ccc(Oc3cccc(Cl)c3)cc12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FADS1 O60427 3/20 0.41
▸ CARM1 Q86X55 3/20 0.41
▸ PRMT1 Q99873 3/20 0.41
▸ PRMT5 O14744 1/20 0.37
▸ WDR77 Q9BQA1 1/20 0.37
▸ SLC6A4 P31645 3/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ SLC6A3 Q01959 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ MGLL Q99685 1/20 0.34
▸ MCHR1 Q99705 1/20 0.34
▸ EGFR P00533 1/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ HSP90AB1 P08238 1/20 0.33
▸ TTBK1 Q5TCY1 1/20 0.33
▸ ACHE P22303 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17469497 0.91 PRMT1 (0.38) FADS1CARM1PRMT1PRMT5WDR77
SCHEMBL16120045 0.89 TTK (0.39) CARM1PRMT1
SCHEMBL17469445 0.89 FADS1 (0.40) FADS1PRMT1PRMT5WDR77HTR2A
SCHEMBL17469470 0.89 HSP90AA1 (0.37) CARM1PRMT1MGLLHSP90AA1HSP90AB1
SCHEMBL17469453 0.86 PRMT1 (0.42) PRMT1
SCHEMBL17469513 0.85 PRMT5 (0.40) PRMT1PRMT5WDR77KCNH2
SCHEMBL17469449 0.85 PRMT1 (0.37) CARM1PRMT1PRMT5WDR77HTR2A
SCHEMBL17469509 0.85 PRMT1 (0.43) FADS1PRMT1PRMT5WDR77SLC6A2
SCHEMBL17469478 0.85 CARM1 (0.42) CARM1PRMT1PRMT5WDR77SLC6A4
SCHEMBL17469504 0.82 HTR2A (0.44) FADS1PRMT1SLC6A4SLC6A2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180105497-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2018-04-19 — — US disclosed
US-20180105497-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2018-04-19 — — US disclosed
US-20180105497-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2018-04-19 — — US disclosed
US-9765035-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2017-09-19 — — US disclosed
US-9765035-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2017-09-19 — — US disclosed
US-9765035-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2017-09-19 — — US disclosed
US-20160024017-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-01-28 — — US disclosed
US-20160024017-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-01-28 — — US disclosed
US-20160024017-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-01-28 — — US disclosed
WO-2014153235-A2 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024017-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 FADS1 2222/4885CARM1 12/4885PRMT1 1/4885
US-20180105497-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 FADS1 2222/4885CARM1 12/4885PRMT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback